N/A N=63 Gastric Outlet Obstructions Tailored Covered Stents for GOO
Gastric Outlet Obstruction
Primary: Efficiency of Stents — 1; 7 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=17 Comparison of Duodenal Stenting vs Transpyloric and Duodenal Stenting for Malignant Obstruction
Duodenal Obstruction
Primary: Number of Participants With Any Change (2 Point Increase or Decrease) in Symptoms From Baseline — 7; 6 Participants
N/A N=100 Gastric Ultrasound
Surgery
Primary: Aspiration Risk Grade — 30; 30; 20; 9 Participants
N/A N=7 Evaluation of Pancreatobiliary Disorders in Patients With Altered Gastric Anatomy
Pancreatobiliary Disease · Altered Gastric Anatomy
Primary: Papilla or Duct-enterostomy Was Reached — 10 ERCPs
N/A N=60 Perianastomotic Drain After Gastrectomy (DRAG)
Gastric Cancer
Primary: a) Number of Participants With High Pain Levels (Using the Visual Analog Scale) — 31; 3 Participants
N/A N=199 S1316, Surgery or Non-Surgical Management in Treating Patients With Intra-Abdominal Cancer and Bowel Obstruction
Constipation, Impaction, and Bowel Obstruction · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Number of Days Alive and Outside of the Hospital — 42.6; 43.9; 54.8; 52.7 days — p=0.50
N/A N=20 Endoscopic Suturing for Primary Obesity Treatment
Obesity · Body Weight · Overweight
Primary: Number of Participants With Adverse Events — 5; 2; 0; 13 Participants
Phase 2 N=52 Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction
Intestinal Obstruction
Primary: Percentage of Responders Before or at Day 7 — 88.2; 25.7; 46.2 percentage of responders — p=0.0055
N/A N=150 Gastric Procedures for Obesity
Morbid Obesity
Primary: Change in Body Weight — -21.4; -36.6; -7.0 kg
N/A N=130 Staging and Outcome Depending on Surgical Treatment in Adenocarcinomas of the Oesophagogastric Junction
Esophageal Carcinoma
Primary: Overall Survival — 12; 11; 13 participants
N/A N=53 Gastroesophageal Reflux Disease (GERD) Before and After Gastric Bypass
Gastroesophageal Reflux Disease · Morbid Obesity
Primary: Number of Participants Presenting Reflux Symptoms — 31; 8; 5 participants — p=<0.001
N/A N=7 Feasibility of Translumenal Endoscopic Omental Patch Closure of Perforated Viscus
Peptic Ulcer
Primary: Number of Participants Completing Natural Orifice Translumenal Endoscopic Surgical (NOTES) Repair — 2; 1 participants
Phase 2 N=64 Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis
Peritoneal Neoplasms · Intestinal Obstruction · Carcinomatosis
Primary: Number of Participants With Treatment Success From Day 10 to Day 13 — 12; 9; 19; 13 Participants
N/A N=10 Natural Orifice Transgastric Endoscopic (NOTES) Transgastric Diagnostic Peritoneoscopy With Laparoscopic Assistance
Abdominal Adhesions
Primary: Completion of Diagnostic Peritineoscopy — 8 Participants
N/A N=15 Assessment of Gastric Volume Reduction in Surgical Weight Loss Candidates
Obesity
Primary: Successful Gastric Plication Using Reduction Gastroplasty — 9; 6 participants
N/A N=24 Endoscopic Surgery for Bariatric Revision After Weight Loss Failure
Morbid Obesity · Weight Loss
Primary: Mean Weight Loss — 13.3 Pounds
N/A N=355 Evaluation of Endostapled Anastomoses for Laparoscopic Gastric Bypass (EEA-LGB)
Morbid Obesity
Primary: Number of Participants With Postoperative Gastrointestinal Hemorrhage — 13; 39 participants
Phase 2 N=14 Evaluation of the Safety and Effectiveness of Stomaphyx for Transoral Incisionless Reduction of the Enlarged Gastric Pouch and Stoma
Morbid Obesity
Primary: Primary Outcome: Change in Body Weight — 9.6 kg
N/A N=5 Gastric Artery Embolization Trial for Lessening Appetite Nonsurgically
Arterial Embolization · Other Surgical Procedures · Obesity
Primary: Body Weight Average 6 Months Post-Procedure — 237.6 lbs.
Phase 4 N=60 Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy
Diabetes Mellitus, Type 2 · Obesity · Gastroparesis
Primary: Presence of RGV (Residual Gastric Volume) in Stomach — 7; 1 Participants
N/A N=62 Comparison Between Pyloric Preserving and Non-Pyloric Preserving Bariatric Surgery With Glucose Challenge
Hypoglycemia · Obesity
Primary: Mean Serum Glucose Levels — 123.1; 157.5; 103.2; 138 mg/dl
Phase 3 N=15 Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial
Gastric Cancer
Primary: Overall Survival in Patients With Limited Metastatic Gastric Carcinoma: Arm I — 19; 11; 11; 4 Months
Phase 2 N=110 Metoclopramide Versus Placebo for GJ Placement
Radiation Exposure · Enteral Nutrition
Primary: Time to Duodenal Intubation — 1.6; 4.1 Minutes
Phase 4 N=75 Study of Stapled Transanal Rectal Resection (STARR) Surgery in Refractory Constipation Associated With Obstructive Defecation Syndrome (ODS)
Obstructive Defecation Syndrome · Chronic Constipation · Rectocele
Primary: Percentage of Change (Reduction) in Total ODS Symptom Composite Score From Baseline to One Year Post Procedure — 60.8 percentage of change
N/A N=30 Ileal Interposition With Sleeve Gastrectomy for Control of Diabetes
Diabetes
Primary: Percentage of Participants Having Remission of Type 2 Diabetes — 76.66 Percentage of Participants
Phase 3 N=58 Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis
Gastroparesis
Primary: Symptom of Vomiting Associated With Gastroparesis — 1.82; 2.68; 0.17; 1.20 Patient Self-reported Symptom Score
N/A N=16 Endoscopic Peroral Myotomy for Treatment of Achalasia
Achalasia
Primary: Treatment Success Defined as Symptom Relief 3 Months After Treatment Based on an Eckhardt Score ≤ 3 — 1.4; 8.8 Eckardt Score — p=<0.001
N/A N=32 Placebo Controlled Trial of Botulinum Toxin for Gastroparesis
Gastroparesis
Primary: Symptom Response as Assessed by the Gastroparesis Cardinal Symptom Index. — 6.8; 10.1 units on a scale
N/A N=15 Safety and Efficacy of Long Limb Roux-en Y Reconstruction
Diabetes Mellitus Type 2 in Nonobese · Gastric Cancer
Primary: Morbidity — 4 participants
N/A N=5 Gastrectomy, Eating Behaviour and GLP-1
Gastric Cancer · Dumping Syndrome
Primary: Nadir Blood Glucose — 3; 4.4 mmol/l — p=0.008